Knight Therapeutics Inc T.GUD

Alternate Symbol(s): KHTRF

Healthcare Biotechnology

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.

TSX:GUD - Post by User

Knight Therapeutics Inc

Bullboard Posts

Comment by Troy23on Mar 22, 2014 5:57pm

210 Views

Post# 22356188

RE:RE:GUD worth $24 with current assets

Correct me if I am wrong

1.765 Billion at 23$ per share means roughly 76 000 000 shares. Aren't we at 22 000 000 + 34 000 000 right now?? So, 56 000 000?? That would mean 31$ per share

I may be wrong, this is just from my understanding of the latest financing.

Bullboard Posts

Quantum eMotion leaps by 20 per cent after Becton Dickinson deal